Interview

For the Record with Michael Hoey, Founder and CTO, Francis Medical

March 22, 2021

For the Record Michael Hoey

In an interview for Medical Alley’s For the Record, the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical…

Read the Medical Alley Article

Share this post

Recent Posts

  • Dr. Su
Francis Medical Announces Orange County Urology Associates Becomes First in California to Integrate Vanquish® Water Vapor Ablation into Routine Prostate Care

July 7th, 2026|

Maple Grove, Minn., July 7th, 2026 – Daniel Su, MD, a urologist at Orange County Urology Associates (OCUA), has performed the first commercial Vanquish® Water Vapor Ablation procedures in the state of California, offering patients a new minimally invasive Focal Therapy option as part of the group’s prostate care service. The procedure was completed within a single outpatient visit and did not require a hospital stay. Beyond the clinical milestone, Dr. Su’s experience highlights something equally important: how this technology can be adopted into an existing urology practice.

Francis Medical Announces Publication of VAPOR 2 Pivotal Trial Results in The Journal of Urology

June 30th, 2026|

MAPLE GROVE, Minn., June 30, 2026 – Francis Medical, Inc., a medical device company dedicated to advancing minimally invasive therapies for urological cancers, today announced the publication of the initial report from its VAPOR 2 pivotal clinical study in The Journal of Urology, one of the world’s leading peer-reviewed urology journals.

University of Chicago Urologist Performs First Commercial Vanquish® Water Vapor Ablation Procedure in the State

May 28th, 2026|

Chicago, IL [May 28, 2026] – Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first commercial Vanquish® Water Vapor Ablation procedure in the Chicago metropolitan area, marking a significant milestone for patients in the region seeking minimally invasive prostate treatment options.